BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to treat cancer. Get up to date with the BeiGene hematology pipeline and clinical trials.

Factsheet describing the effectiveness and safety of a BTKi treatment in patients with treatment naïve chronic lymphocytic leukemia (TN CLL).

Factsheet describing the effectiveness and safety of a BTKi treatment in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).

Overview of current advances in and future approaches to CLL management with BTK and Bcl-2 inhibitors, with patient cases illustrating criteria for treatment selection and sequencing and reference to new guidelines.